The therapeutic potential of aqueous extract of Falcaria vulgaris in the treatment of fatty liver disease: a histopathological and biochemical approach

2018 ◽  
Vol 28 (4) ◽  
pp. 955-961 ◽  
Author(s):  
Samaneh Goorani ◽  
Mohsen Zhaleh ◽  
Mohammad Kazem Koohi ◽  
Niloofar Seydi ◽  
Khodabakhsh Rashidi ◽  
...  
2011 ◽  
Vol 30 (1) ◽  
pp. 6-19 ◽  
Author(s):  
Haim Shapiro ◽  
Miryam Tehilla ◽  
Joelle Attal-Singer ◽  
Rafael Bruck ◽  
Rachel Luzzatti ◽  
...  

2014 ◽  
Vol 23 (3) ◽  
pp. 311-319 ◽  
Author(s):  
Yasar Colak ◽  
Atakan Yesil ◽  
Hasan Huseyin Mutlu ◽  
Ozge Telci Caklili ◽  
Celal Ulasoglu ◽  
...  

Sirtuins (SIRTs) are members of the silent information regulator-2 family and act as nicotinamide adenine dinucleotide (NAD+)-dependent histone/protein deacetylases. The de-acetylation of proteins and histones results in an up- or down-regulation of gene transcription and protein function. In recent years, the regulatory action of the deacetylation activity of SIRT1 has been shown to have a positive impact on the pathophysiological mechanisms of nonalcoholic fatty liver disease (NAFLD). Among the effects of SIRT1 are: its healing activity on insulin sensitivity, thereby ameliorating glycemic regulation; its mimetic activity on calorie restriction; its antihyperlipidemic activity on lipid homeostasis via the liver, adipose tissues and skeletal muscles; its antiinflammatory activities; its protective effects against cardiovascular events and endothelial dysfunction; its positive influence on autophagy, apoptosis and cancer; and finally, its anti-aging activity. The current approach for the treatment of NAFLD involves the treatment of etiological factors and recommendation of life-style changes including more physical activity and a low-calorie diet. However, there are no specific medical treatments for NAFLD. The therapeutic potential of SIRT1 activity in the treatment of NAFLD discovered in humans has been presented in this article. In this review, the potential effects of SIRT1 activation on NAFLD-related pathophysiological mechanisms and on the treatment of NAFLD are discussed.


2019 ◽  
Vol 847 ◽  
pp. 72-82 ◽  
Author(s):  
Marwa B. Bakir ◽  
Mona A. Salama ◽  
Rowaida Refaat ◽  
Mennatallah A. Ali ◽  
Eman A. Khalifa ◽  
...  

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0172900 ◽  
Author(s):  
María Eugenia Inzaugarat ◽  
Elena De Matteo ◽  
Placida Baz ◽  
Diego Lucero ◽  
Cecilia Claudia García ◽  
...  

Nutrients ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 872 ◽  
Author(s):  
Jinchunzi Yang ◽  
Marta Fernández-Galilea ◽  
Leyre Martínez-Fernández ◽  
Pedro González-Muniesa ◽  
Adriana Pérez-Chávez ◽  
...  

Aging is a complex phenomenon characterized by the progressive loss of tissue and organ function. The oxidative-stress theory of aging postulates that age-associated functional losses are due to the accumulation of ROS-induced damage. Liver function impairment and non-alcoholic fatty liver disease (NAFLD) are common among the elderly. NAFLD can progress to non-alcoholic steatohepatitis (NASH) and evolve to hepatic cirrhosis or hepatic carcinoma. Oxidative stress, lipotoxicity, and inflammation play a key role in the progression of NAFLD. A growing body of evidence supports the therapeutic potential of omega-3 polyunsaturated fatty acids (n-3 PUFA), mainly docosahaexenoic (DHA) and eicosapentaenoic acid (EPA), on metabolic diseases based on their antioxidant and anti-inflammatory properties. Here, we performed a systematic review of clinical trials analyzing the efficacy of n-3 PUFA on both systemic oxidative stress and on NAFLD/NASH features in adults. As a matter of fact, it remains controversial whether n-3 PUFA are effective to counteract oxidative stress. On the other hand, data suggest that n-3 PUFA supplementation may be effective in the early stages of NAFLD, but not in patients with more severe NAFLD or NASH. Future perspectives and relevant aspects that should be considered when planning new randomized controlled trials are also discussed.


Author(s):  
Somasekhar Reddy Kanala ◽  
Sudheer Akkiraju ◽  
Likitha Sree Pamisetty ◽  
Pradeepkumar Bhupalam ◽  
Deepthi Dharmavaram ◽  
...  

2017 ◽  
Vol 2 (2) ◽  
pp. 1
Author(s):  
Obayuwana E, Obayuwana E, Ubehenin A.E, Innih S.O, Iwee R, Eidaghese E.C

Moringa oleifera belongs to family of moringaceae and is considered as one of the world’s most useful trees, as almost every part of the plant can be used for either as food, or therapeutic purposes. Fatty diet is a significant factor in the pathogenesis of non-alcoholic fatty Liver disease (NAFLD). The study was designed to examine histological effects of aqueous extract of Moringa oleifera on the liver tissues of wistar rat fed with high fat diet. Twenty five adult rats were divided into five groups of five animals each .While group A received distilled water daily only, groups Band C received aqueous extract of Moringa oleifera at doses of 200 mg/kg body weight and fat high diet (30% w/w of the total mash feed) respectively for a duration of seventy days. Others (groups D and E) received aqueous extract of Moringa oleifera at doses of 200 mg/kg body weight and fat high diet for a duration of seventy days. Histology of the liver of the rats fed with high fat diet exhibited significant changes in the architecture of liver tissue. The changes include micro and macro vascular steatosis, increased fatty infiltration, inflammation, sinusoidal dilation, degeneration of veins and vacuolization as compared to normal liver histology. Treatment with 200 mg/kg extract of Moringa oleifera significantly attenuated these effects imposed by high fat diet as compared to the control group. Therefore demonstrated that daily administration of Moringa oleifera leaves extract to rats for a period of 70 days may reverse the formation of hepatic steatosis in non-alcoholic fatty liver disease.


Sign in / Sign up

Export Citation Format

Share Document